Araniy Santhireswaran, Shanzeh Chaudhry, Martin Ho, Kaitlin Fuller, Etienne Gaudette, Lisa Burry, Mina Tadrous
{"title":"Impact of Supply Chain Disruptions and Drug Shortages on Drug Utilization: A Scoping Review.","authors":"Araniy Santhireswaran, Shanzeh Chaudhry, Martin Ho, Kaitlin Fuller, Etienne Gaudette, Lisa Burry, Mina Tadrous","doi":"10.1002/pds.70178","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Drug shortages are a growing challenge in health systems across the world. A better understanding of the impacts of shortages on patient drug access and use will guide policies aimed at mitigating shortages. This scoping review aims to summarize observational literature assessing the impact of drug shortages on drug utilization trends.</p><p><strong>Methods: </strong>We searched Ovid MEDLINE and Ovid EMBASE for studies published between 1946 and September 17, 2024. An extensive grey literature search was conducted through targeted website searches, grey literature databases, and the Google search engine. Observational studies examining the impacts of drug shortages on drug use were included. Study screening and extraction were conducted by two independent reviewers.</p><p><strong>Results: </strong>We identified 55 published articles and five gray literature reports. Most studies were conducted in North America (n = 42, 70%). Population-level data were most used (n = 34, 57%), and most studies used drug prescription data to assess changes in use (n = 30, 55%). Most studies reported changes in drug use as a percent change, and the magnitude in decreases ranged from 1% to 99%. Many different data sources, methods, and measures were used to study the impact of drug shortages on drug utilization, and a broad range of decreases in drug utilization following the shortages were reported.</p><p><strong>Conclusions: </strong>It is important to synthesize findings across studies to understand how different drugs and settings are affected by shortages. The findings here will inform future studies aimed at filling this knowledge gap, ultimately yielding real-world evidence that can guide policy decisions to address drug supply challenges.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 7","pages":"e70178"},"PeriodicalIF":2.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215599/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70178","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Drug shortages are a growing challenge in health systems across the world. A better understanding of the impacts of shortages on patient drug access and use will guide policies aimed at mitigating shortages. This scoping review aims to summarize observational literature assessing the impact of drug shortages on drug utilization trends.
Methods: We searched Ovid MEDLINE and Ovid EMBASE for studies published between 1946 and September 17, 2024. An extensive grey literature search was conducted through targeted website searches, grey literature databases, and the Google search engine. Observational studies examining the impacts of drug shortages on drug use were included. Study screening and extraction were conducted by two independent reviewers.
Results: We identified 55 published articles and five gray literature reports. Most studies were conducted in North America (n = 42, 70%). Population-level data were most used (n = 34, 57%), and most studies used drug prescription data to assess changes in use (n = 30, 55%). Most studies reported changes in drug use as a percent change, and the magnitude in decreases ranged from 1% to 99%. Many different data sources, methods, and measures were used to study the impact of drug shortages on drug utilization, and a broad range of decreases in drug utilization following the shortages were reported.
Conclusions: It is important to synthesize findings across studies to understand how different drugs and settings are affected by shortages. The findings here will inform future studies aimed at filling this knowledge gap, ultimately yielding real-world evidence that can guide policy decisions to address drug supply challenges.
期刊介绍:
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.
Particular areas of interest include:
design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
assessments of harm versus benefit in drug therapy;
patterns of drug utilization;
relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.